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Abstract
Antileukoproteinase (ALP) is a physiological inhibitor of
granulocytic serine proteases that has been shown to have anti-
inflammatory properties in addition to its antiproteolytic activity.
On the basis of its potential to block anti-collagen type II (CII)
antibody-induced arthritis (CAIA) and to suppress the
conformational activation of β2-integrins in leukocytes, the
present study was undertaken to investigate its interference with
leukocyte adherence to cytokine-activated endothelium. The
potential of recombinant ALP to block the interactions of
leukocytes with the endothelial lining was concomitantly
investigated in vitro and in vivo. Thus, intravital fluorescence
microscopic imaging of leukocyte rolling and firm adhesion to
postcapillary venules were performed in the knee joints of
DBA1/J mice after intravenous injection of anti-CII mAbs. An IL-
1β-activated endothelial layer formed by a murine glomerular cell
line (glEND.2) was used to assay the interaction with human
leukocytes in vitro. Electromobility shift and luciferase reporter
gene assays permitted the analysis of cytokine-induced
activation of the NF-κB pathway. Fluorescence-activated cell
sorting was applied to determine endothelial E-selectin
expression. Leukocyte rolling and firm adhesion to the synovial
endothelium in an early response to the anti-CII antibody transfer
were significantly decreased in ALP-pretreated mice.
Concomitantly, ALP suppressed the IL-1β-induced NF-κB
activation and the upregulation of E-selectin expression in
glEND.2 cells in vitro. These findings support the notion that the
newly uncovered properties of ALP to interfere with cytokine
signalling and upregulation of adhesion molecules in endothelial
cells are likely to contribute to the therapeutic potential of ALP
in immune-complex-induced tissue injury.
Introduction
Antileukoproteinase (ALP), also named secretory leukocyte
protease inhibitor (SLPI), is a highly basic (pI > 10), acid-sta-
ble inhibitor of neutrophil serine proteinases (molecular massPage 1 of 11
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against proteolytic attack of the upper respiratory and urogeni-
tal tract, the physiological expression of ALP has also been
demonstrated for a variety of extramucosal cells, including
neutrophils [2] and macrophages [3]. In addition to antiprote-
olytic properties, ALP exerts a variety of anti-inflammatory
actions on monocytes and neutrophils [4,5]. It has also been
proposed that the ability of ALP to downregulate the lipopoly-
saccharide response in macrophages is most probably related
to an inhibitory effect on NF-κB activation [6]. More recently it
has been demonstrated that treatment with ALP significantly
decreased the incidence and severity of anti-collagen type II
(CII) antibody-induced arthritis (CAIA). In addition to clinical
amelioration, decreased leukocytic infiltration of synovial tis-
sue and protective effects on cartilage and bone erosion in
ALP-treated mice was seen [5]. The effect on leukocyte
extravasation and tissue destruction could be ascribed, at
least partly, to the interference of ALP with cytoskeletal
changes in Fc-receptor-stimulated granulocytes [5]. The
downmodulation of stimulation-induced F-actin assembly in
neutrophils through the interaction of ALP with the actin-bun-
dling protein l-plastin caused a blockade of the conformational
activation of β2-integrins [5].
Because regulating the avidity of leukocyte β2-integrins LFA-1
(CD11a/CD18) and Mac-1 (CD11b/CD18) is critical for the
recruitment of leukocytes into inflamed tissues [7-9] we
focused the present investigation of ALP effects on the initial
steps of leukocyte interaction with the endothelial layer after
an inflammatory stimulus. A statistical analysis of intravital
microscopic images recorded from the knee joints of
untreated control mice during an early time span of 24 hours
after the transfer of anti-CII mAbs [10] revealed an antibody-
induced increase in leukocyte adhesion to the vessel walls.
Preventive administration of ALP as a single dose of 100 µg
per mouse led to a significant suppression of leukocyte rolling
on, and of firm adhesion to, the synovial venular endothelium.
Accompanying experiments in vitro with IL-1β-activated
endothelial cells demonstrated the capacity of ALP to sup-
press the cytokine-induced increase in leukocyte adhesion.
Moreover, an inhibitory effect of ALP preincubation on IL-1β-
induced endothelial E-selectin surface expression was
recorded by fluorescence-activated cell sorting (FACS) analy-
sis of anti-E-selectin antibody-stained glEND.2 cells (a murine
glomerular cell line). The subsequent elucidation of a suppres-
sive effect of ALP on IL-1β-induced NF-κB activation in
glEND.2 cells also suggests that the modulation of this signal-
ling pathway is probably involved in the ALP-dependent inhibi-
tion of IL-1β-induced E-selectin expression. Moreover, the
observed suppression of leukocyte rolling in vivo as a selectin-
dependent interaction with the vessel wall [11] is easily recon-
cilable with the newly uncovered blocking effect of ALP on a
crucial cytokine signalling pathway in endothelial cells [12].
This regulatory potential and the inhibition of firm leukocyte
adhesion in vivo by ALP, which probably reflects the already
known interference with β2-integrin activation on leukocytes,
complement each other in their anti-inflammatory effect. This
synergism may contribute to the established capacity of ALP
to block leukocyte infiltration and tissue injury in a variety of
experimental models of inflammation, such as streptococcal
cell wall arthritis [13], CAIA [5] or ischaemia/reperfusion-
induced organ damage [14].
Materials and methods
Anti-CII mAb transfer
The experimental protocol was approved by the local animal
ethics committee and followed the National Institutes of
Health guidelines for the care and use of laboratory animals.
DBA1/J mice were obtained from the Jackson Laboratory (Bar
Harbor, ME, USA). All mice were kept under standard condi-
tions at the animal care facility of the University of Rostock.
For the induction of immune-complex-induced inflammation,
14-week-old mice (n = 8 per group) received two mAbs
(CIIC1 and M2.139 [5,15]; 4.5 mg of each) intravenously into
the caudal vein. Simultaneously the animals were treated with
either 100 or 300 µg of recombinant human ALP [5,16] (kindly
provided by Dr Heinzel-Wieland, Darmstadt, Germany) or 300
µg of a control protein (human serum albumin; Octapharma,
Langenfeld, Germany), or received an equal volume of saline
only. After 6 and 24 hours, animals (n = 6 to 8 per time point)
were anaesthetized with ketamine (90 mg/kg body weight)
and xylacin (6 mg/kg) for subsequent in vivo multifluorescence
microscopy. Animals were placed on a heating pad to maintain
a body temperature of 37°C and a catheter was placed in the
left jugular vein for the application of fluorescent dyes. For in
vivo multifluorescence microscopy of synovial microcircula-
tion, the knee joint model was used as described [17]. In brief,
skin was incised distal to the patella tendon. After removal of
the overlying soft tissues, the patella tendon was cut trans-
versely and the proximal and distal parts carefully mobilized.
After exposure, the Hoffa's fatty body was superfused with
physiological saline solution ay 37°C to prevent tissues from
drying and was finally covered with a glass slide. After a 15-
minute stabilization period after surgical preparation, in vivo
microscopy of the synovial tissue was performed. At the end
of each experiment the animals were killed by exsanguination.
Recombinant ALP
Human ALP was produced as a recombinant protein in
Escherichia coli and subsequently purified to homogeneity by
a multistep purification protocol by ion-exchange, metal-
chelate and size-exclusion chromatography as originally
described by Heinzel-Wieland and colleagues [16]. Analytical
reverse-phase chromatography revealed a single peak, and
SDS-PAGE exhibited a single band with the expected electro-
phoretic mobility on being stained with silver. The material was
tested for inhibition of granulocyte elastase and cathepsin G.
To ensure the removal of any endotoxin contamination, the
ALP charges were run on detoxi-gel columns (polymyxin B-Page 2 of 11
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accordance with the manufacturer's instructions. Routine test-
ing of the final ALP preparations before use demonstrated that
for all analysed samples the endotoxin content remained
below the detection limit (0.05 U/ml) of the applied Limulus
amoebocyte lysate gel-clot assay (Sigma, Taufkirchen,
Germany).
In vivo fluorescence microscopy
After intravenous injection of fluorescein isothiocyanate
(FITC)-labelled dextran (15 mg/kg body weight) (Sigma,
Deisenhofen, Germany) and rhodamine 6G (0.15 mg/kg body
weight) (Sigma), in vivo microscopy was performed with a
Zeiss microscope (Axiotech Vario 100HD; Carl Zeiss, Jena,
Germany) equipped with a 100 W mercury lamp and filter sets
for blue (excitation at 465 to 495 nm; emission at more than
505 nm) and green (excitation at 510 to 560 nm; emission at
more than 575 nm) epi-illumination. By the use of water-immer-
sion objectives (× 20 W/numerical aperture (NA) 0.5 and × 40
W/NA 0.8; Zeiss) final magnifications of × 306 and × 630
were achieved. Images were recorded by means of a charge-
coupled device video camera (FK 6990-IQ-S; Pieper, Schw-
erte, Germany) and transferred to an S-VHS video system for
subsequent off-line analysis.
Microcirculatory analysis
For quantitative off-line analysis a computer-assisted microcir-
culation image analysis system was used (CapImage v.7.4;
Zeintl, Heidelberg, Germany). For the assessment of interac-
tion between leukocytes and endothelial cells in postcapillary
venules, the flow behavior of leukocytes was analysed with
respect to free floating, rolling and adherent leukocytes
[17,18]. Rolling leukocytes were defined as those cells mov-
ing along the vessel wall at a velocity less than 40% of that of
leukocytes at the centreline and were expressed as a percent-
age of the total leukocyte flux. Venular leukocyte adherence
was defined as the number of leukocytes not moving or
detaching from the endothelial lining of the venular vessel wall
during an observation period of 20 seconds. Assuming cylin-
drical microvessel geometry, leukocyte adherence was
expressed as non-moving cells per endothelial surface (n/
mm2), calculated from the diameter and length of the vessel
segment analysed.
Statistical analysis
Results are given as means ± SEM. After proving the assump-
tion of normality, comparisons between the experimental
groups were performed by one-way analysis of variance
(ANOVA), followed by the appropriate post-hoc multiple com-
parison procedure, including Bonferroni correction. Statistical
significance was set at p < 0.05.
Isolation of human granulocytes
Blood cells were obtained from heparinized venous blood from
healthy donors. In brief, granulocytes were isolated by discon-
tinuous Percoll density gradient centrifugation with 70% and
62% Percoll (Biochrom, Berlin, Germany). The phase contain-
Figure 1
Inhibition of leukocyte interaction with the postcapillary endothelium by ALP n vivo
ALP in vivo. (a) Inhibition of leukocyte rolling along the postcapillary 
endothelium by antileukoproteinase in vivo. The results show the frac-
tion of leukocytes rolling along the endothelium of postcapillary synovial 
venules (expressed as a percentage of all passing leukocytes) in anti-
collagen II (CII) antibody-induced DBA1/J mice pretreated with either 
antileukoproteinase (ALP; 100 and 300 µg), human serum albumin 
(hSA, 300 µg) or NaCl in comparison with healthy mice (HC) that did 
not receive the antibody challenge. Intravital fluorescence microscopy 
of the knee joints was performed at 6 and 24 hours after the systemic 
transfer of anti-CII mAb. Results are shown as means and SEM for n = 
8 animals per group; *p < 0.05. (b) Inhibition of leukocyte adherence to 
the postcapillary endothelium by ALP in vivo. The results show the 
number of leukocytes adherent to the endothelium of postcapillary syn-
ovial venules (expressed as cells per mm2 endothelial surface) in anti-
CII antibody-induced DBA1/J mice pretreated with either ALP (100 and 
300 µg), hSA (300 µg) or NaCl in comparison with healthy mice (HC) 
that did not receive the antibody challenge. Intravital fluorescence 
microscopy of the knee joints was performed at 6 and 24 hours after 
the systemic transfer of anti-CII mAb. Results are shown as means and 
SEM for n = 8 animals per group; *p < 0.05.Page 3 of 11
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and washed with PBS. Contaminating erythrocytes were
removed by hypotonic lysis and a subsequent centrifugation
step. The purified granulocytes were recovered from the cell
pellet and resuspended in DMEM at a final concentration of
106 cells/ml.
Leukocytes adhesion assay
The leukocyte adhesion assays were performed as described
by Hammel and colleagues [19], with slight modifications.
glEND.2 cells were produced and characterized as described
for mlEND.1 cells [20]. They were seeded on Labtek chamber
slides (6 × 104) and grown to confluence. glEND.2 cells were
incubated for 2 hours with different concentrations of ALP
(100 nM to 5 µM). The upregulation of adhesion molecules on
the glEND.2 cells was induced by activating the cells with IL-
1β (20 ng/ml, R&D Systems GmbH, Wiesbaden, Germany)
for 4 hours at 37°C. The cells were washed intensively with
DMEM and the freshly isolated human granulocytes were
added in a volume of 200 µl to the endothelial cell layer and
agitated horizontally at 75 r.p.m. for 20 minutes at 4°C. Cells
were washed carefully three times in DMEM and fixed over-
night in 2.5% glutardialdehyde (Roth, Karlsruhe, Germany).
On the next day, the adherent cells were evaluated by direct
microscopic counting of four randomly chosen visual fields.
Some experiments were performed with the human endothe-
lial cell line EA.hy 926 that was originally derived by the fusion
of human umbilical-vein endothelial cells with the epithelial cell
line A549 [21]. In that case the granulocytes were prelabelled
with carboxyfluorescein diacetate succinimidyl diester (CFDA-
SE), Molecular Probes, Eugene, OR, USA), to facilitate the
counting of adherent granulocytes in randomly chosen visual
fields by fluorescence microscopy (× 10/NA 0.3, objective
Axiophot; Zeiss) as described [22].
E-selectin expression analysis by FACS
glEND.2 cells were seeded on 48-well plates (4 × 104) in
complete low-glucose DMEM and grown to 80% confluence.
ALP treatment was performed after a PBS washing step with
2 to 12 µM ALP for 2 hours at 37°C. Medium was removed
and the cells were washed twice with PBS and activated for 4
hours with 20 ng/ml IL-1β. E-selectin expression was detected
on staining with a rat anti-mouse CD62E-biotin (dilution
1:400; BD Biosciences Pharmingen, San Diego, CA, USA)
antibody and phycoerythrin-labelled avidin (dilution 1:1,000;
BD Biosciences Pharmingen). After a final centrifugation, the
cells were resuspended in 1 ml of PBS and their fluorescence
was measured by flow cytometry in a Coulter Epics XL flow
cytometer (Beckman CoulterCorp., Miami, FL, USA). For the
analysis, the gates of forward and sideways light scatter were
set on the glEND.2 cell population. The average of E-selectin
expression in the endothelial cell population was expressed as
the mean of the fluorescence intensity.
Analysis of nuclear NF-κB DNA binding activity
glEND.2 cells were grown to 80% confluence in 75 cm3 cul-
ture flasks and treated with different concentrations of ALP
Figure 2
Imaging of adherent leukocytes in vivo. The figure shows a representa-
tive fluorescence microscope image (original magnification × 306) of a 
postcapillary venule showing an increased number of cells adhering to 
the wall of the postcapillary venule in a control animal that received the 
anti-collagen II (CII) antibodies and a pre-treatment with NaCl com-
pared to an antileukoproteinase-treated mouse at 24 hours after anti-
CII mAb transfer.
Figure 3
Inhibition of leukocyte attachment to IL-1β-activated glEND.2 cells by ant leukoprot inase in vi ro
antileukoproteinase in vitro. The adherence of human granulocytes to 
layers of glEND.2 cells was assessed microscopically. The quantitative 
measure for leukocytes adhering to the glEND.2 cells under the 
respective incubation conditions is expressed as a percentage of the 
positive control, which is the mean number of adherent cells to IL-1β-
activated endothelium in medium (+IL-1β control; stimulation with 20 
ng/ml IL-1β for 4 hours). The percentages of adherent leukocytes to 
glEND.2 cells were derived from eight independent experiments and 
are expressed as means and SEM for the following experimental condi-
tions: no stimulus (- IL-1β control), IL-1β stimulation after pretreatment 
with either antileukoproteinase (ALP) or with human serum albumin 
(hSA) (0.1, 1 or 5 µM) as a control protein for 2 hours. The inhibitory 
effect of pretreatment with ALP on granulocyte adherence was statisti-
cally significant at 1 and 5 µM (*p < 0.01; analysis of variance with cor-
rection for multiple testing).Page 4 of 11
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washing step, cells were activated with 10 ng/ml IL-1β for 1
hour. Subsequently, electrophoretic mobility-shift assay
(EMSAs) of nuclear extracts from ALP-treated and untreated
glEND.2 cells were prepared as described [23]. In brief, cells
were resuspended in 200 µl of hypotonic lysis buffer A (10
mM HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA, 1 mM dithio-
threitol) and incubated on ice for 15 minutes before the addi-
tion of 5 µl of 10% Nonidet P40. After vortex-mixing, the nuclei
of the lysed cells were collected by centrifugation, washed
once in buffer A and subjected to a subsequent protein extrac-
tion procedure by vortex-mixing vigorously in 50 µl of hyper-
tonic extraction buffer B (10 mM HEPES pH 7.9, 400 mM
NaCl, 1 mM EDTA, 1 mM dithiothreitol). The nuclear proteins
were obtained by collecting the supernatants after centrifuga-
tion. The protein concentration of each extract was measured
with the micro-bicinchoninic acid (BCA) assay reagents from
Pierce (Rockford, IL, USA).
NF-κB binding reactions were performed with 5 µg of nuclear
proteins and a 32P-labelled double-stranded oligonucleotide
containing the NF-κB consensus sequence derived from the
mouse κ intronic enhancer (5' -GATCAGAGGGGACTTTC-
CGAG-3'). Approximately 20,000 c.p.m. of the labelled dou-
ble-stranded oligonucleotide was applied to each binding
reaction. After incubation for 10 minutes at room temperature
the nuclear proteins were separated by electrophoresis on a
5% nondenaturing polyacrylamide gel. For specificity, control
blocking experiments were run with unlabelled specific dou-
ble-stranded oligonucleotides or a respective mutant variant
(5' -CATCAGAGGCGACTTTCCGAGGGATG-3') at 10-fold
and 100-fold molar excess of the labelled NF-κB probe. Sub-
sequently, the electrophoresis gels were dried, exposed on a
PhosphoImager plate and analysed with a FLA-3000 laser-
based imaging system (Fujifilm Europe GmbH, Düsseldorf,
Germany). For normalization of the nuclear translocation of
NF-κB in a quantitative analysis, aliquots (5 µg) of the nuclear
proteins were assessed in parallel for their binding activity to a
32P-labelled double-stranded oligonucleotide containing the
specific recognition sequence of the constitutively active tran-
scription factor Oct-1 (5' -CTGTCGAATGCAAATCACTA-
GAAG-3'). The numerical proportion between NF-κB-binding
and Oct-1-binding activity as determined by the PhosphoIm-
ager in c.p.m. served as the parameter of NF-κB activation.
NF-κB-luciferase reporter assay
For transient transfection, 4× 104 glEND.2 cells grown in 24-
well trays were transfected with a NF-κB reporter plasmid,
pBIIx-luc [24,25], using the Fugene6 transfection reagent
(Roche Diagnostics, Mannheim, Germany). All DNA/Fugene6
incubations were performed at a ratio of 1.5 µg of DNA to 3 µl
of Fugene6 in accordance with the manufacturer's recom-
mended protocol, in DMEM (PAA Laboratories, Pasching,
Austria). After 24 hours, transfected and control glEND.2 cells
were treated for 2 hours with 8 to 20 µM ALP. The activation
of the luciferase reporter gene was induced by 10 ng/ml IL-1β
for 4 hours and monitored by the application of a commercial
luciferase reporter assay. On cell lysis, luciferase activity was
determined in accordance with the instructions of the manu-
facturer of the luciferase assay kit (Promega, Mannheim, Ger-
many) with a luminometer (Luminat LB 9501; Berthold).
Protein concentrations of cell lysates were determined with
the bicinchoninic acid micro-assay method (Pierce, Bonn,
Germany).
Results
Effect of ALP on initial leukocyte-endothelial-cell 
interaction in the synovial microcirculation after anti-CII 
antibody transfer
Although the systemic administration of the anti-CII mAb did
not cause clinical signs of arthritic disease in the knee joints
investigated by intravital microscopy within the first 24 hours,
inflammatory cell responses in the synovial tissue were clearly
provoked. Activation by inflammatory stimuli after antibody
transfer to the mice was indicated by increases in leukocyte
rolling along and attachment to the venular endothelium (Fig-
ure 1). These microcirculatory alterations are not spontane-
ously occurring phenomena in the knee joints of uninduced
Figure 4
Inhibition of leukocyte attachment to IL-1β-treated EA.hy 926 cells by ant leukoprot inase in vi ro
antileukoproteinase in vitro. Adherence of human CFDA-SE (carboxy-
fluorescein diacetate succinimidyl diester)-labelled granulocytes to lay-
ers of EA.hy 926 cells was assessed by fluorescence microscopy. A 
comparison of granulocyte adherence to EA.hy 926 cells that were 
either untreated (- IL-1β) or cytokine-stimulated (+IL-1β) is shown. Pre-
treatment of EA.hy 926 cells with 5 µM antileukoproteinase (ALP) (+IL-
1β +ALP) but not with 5 µM hSA (+IL-1β +hSA) resulted in a marked 
decrease in granulocyte adhesion.Page 5 of 11
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cyte-endothelial-cell interaction induced by the transfer of anti-
CII mAb was significantly (p < 0.05) suppressed in the ALP-
pretreated mice. This blocking effect of ALP on leukocyte
adherence to the vessel intima (Figure 2) occurred on both the
initial rolling and the subsequent phase of firm adhesion. Dose
dependence of inhibition was clearly detectable at 6 hours
after the transfer of anti-CII mAb. Later in the observation
period the suppressive effect declined. However, in this
respect the ALP blockade of firm adhesion was more pro-
nounced and persisted for the entire observation period of 24
hours (Figure 1). The blocking effect was ALP-specific
because human serum albumin (hSA) as an irrelevant control
protein affected neither the antibody-induced increase in leu-
kocyte rolling nor the firm leukocyte adhesion. This result is
consistent with an inhibitory effect of ALP on both selectin-
dependent and integrin-dependent interactions of leukocytes
with the activated synovial endothelium. With regard to the
observed suppression of firm leukocyte adhesion, the effect in
vivo complies very well with the earlier described ALP-induced
blockade of leukocyte β2-integrin activation. However, the
impairment of leukocyte rolling by ALP was rather surprising
and required further investigation.
Effect of ALP on leukocyte adherence to cytokine-
activated endothelial cells in vitro
The model of the IL-1β-activated murine endothelial cell line
glEND.2 permitted the analysis of effects of ALP on granulo-
cyte attachment under conditions that had earlier been proved
to depend partly on selectin-mediated interactions [19]. Prein-
cubation of the endothelial layer with ALP (in 20 µl of PBS car-
rier solution dissolved in DMEM to a final volume of 200 µl)
instead of medium control (200 µl DMEM) before IL-1β activa-
tion resulted in a significantly decreased attachment of purified
human granulocytes (the total cell number per chamber was 2
× 105 per 200 µl) in eight independent experiments, as shown
in Figure 3. In Figure 3 the quantitative measure for leukocytes
that adhered to the glEND.2 cells under the respective incuba-
tion conditions are expressed as percentages of the positive
control (3,782 ± 624 cells in four randomly chosen visual
fields), which is the mean number of cells adhering to IL-1β-
activated endothelium in medium (DMEM). Figure 3 clearly
shows the highly significant decrease (p < 0.01; ANOVA with
Dunnett's correction for multiple testing) in leukocytes adher-
ing to IL-1β-activated glEND.2 cells under pretreatment condi-
tions with ALP (1 µM, 36.25 ± 6.67% (mean ± SEM))
compared with those with the respective control protein hSA
(5 µm, 99.66 ± 18.88%; unstimulated glEND.2 cell control,
10.99 ± 5.79%).
These results suggest that pretreatment with ALP has a block-
ing effect on the subsequent cytokine-induced activation of
selectin-dependent endothelial interactions with leukocytes.
Moreover, the inhibitory effect of ALP is likely to affect primarily
the endothelial cell because a thorough washing procedure
Figure 5
Inhibition of IL-1β-induced upregulation of E-selectin in glEND.2 cells by ALP
by ALP. (a) Inhibition of IL-1β-induced upregulation of E-selectin in 
glEND.2 cells by antileukoproteinase (ALP). Determination of E-selectin 
expression on glEND.2 cells was performed by FACS analysis after 
staining with a biotinylated anti-E-selectin mAb and phycoerythrin-
labelled-streptavidin. The histograms obtained after gating on glEND.2 
cells for forward and sideways light-scattering properties and counting 
of 5,000 events demonstrate the increasing surface expression of E-
selectin in response to stimulation with IL-1β (curve shifted furthest to 
the right) compared with the unstimulated control (leftmost curve). The 
intermediate curve represents the E-selectin distribution on glEND.2 
cells pretreated with ALP (2 µM) before stimulation with IL-1β. (b) Inhi-
bition of E-selectin expression by ALP. Mean fluorescence intensities 
were determined as a measure of the E-selectin expression levels in six 
independent experiments and used to calculate the mean and SEM for 
the following experimental conditions of glEND.2 cell activation: no 
stimulus (- IL-1β control), IL-1β stimulus (+IL-1β), IL-1β stimulation after 
pretreatment with ALP for 2 hours (+IL-1β ALP 2 µM and +IL-1β ALP 
12 µM). The inhibitory effect of pretreatment with ALP on E-selectin 
expression was statistically significant for both concentrations of ALP 
(*p < 0.05).Page 6 of 11
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that the cellular interaction took place after the removal of the
cytokine and the ALP from the medium. Additional experiments
(n = 8) performed with human CFDA-SE-labelled granulo-
cytes and a human endothelial cell line EA.hy 926, an
accepted in vitro model system for the investigation of leuko-
cyte-endothelial-cell interaction [21,22], confirmed the block-
ing effect of ALP on granulocyte adhesion to the IL-1β-
activated endothelial cells. The quantitative assessment of the
experiments, from which four representative panels are shown
in Figure 4, clearly revealed the significant decrease (p < 0.01;
ANOVA) in adherent leukocytes to IL-1β-activated EA.hy 926
cells pretreated with ALP (5 µM, 32.1 ± 5.8%) compared with
hSA (5 µM) control (97.2 ± 15.2%).
Effect of ALP on IL-1β-induced E-selectin upregulation 
on endothelial cells
On the basis of the above experimental evidence for the
capacity of ALP to block leukocyte interaction with cytokine-
activated endothelium to the same extent as specific E-selec-
tin mAbs under similar conditions [19], we considered the
possibility of a direct E-selectin-modulation by ALP and inves-
tigated it further. Thus, E-selectin expression on glEND.2 cells
that were either preincubated with medium or ALP before
stimulation for 4 hours with IL-1β was assessed in parallel by
FACS analysis of the cells stained with anti-E-selectin. The flu-
orescence intensities were determined in six independent
experiments; an example is shown in Figure 5a. The results of
the statistical analysis of the mean fluorescence intensities are
shown. In Figure 5b we demonstrate a significant decrease in
the cell-surface expression of E-selectin on glEND.2 cells that
had been exposed to ALP before the cytokine stimulus (2 µM
ALP, 52.2 ± 4.7 (mean ± SEM); 12 µM ALP, 39.6 ± 6.5) com-
pared with the respective controls without ALP pretreatment
(76.7 ± 9.7; control of unstimulated glEND.2 cells, 10.2 ±
0.7). Our investigations therefore support a direct suppression
of IL-1β-induced E-selectin upregulation in glEND.2 cells by
ALP.
Effect of ALP on IL-1β-induced NF-κB activation in 
endothelial cells
NF-κB has a pivotal role in the cytokine-induced signalling
pathways that lead to an upregulation of E-selectin on the cell
membrane [12]. We therefore analysed the possibility that
ALP interfered with IL-1β-induced NF-κB-signalling in
glEND.2 cells. EMSAs were performed with nuclear extracts
from unstimulated control cells and IL-1β-stimulated glEND.2
cells that had been preincubated in either the presence or the
absence of ALP. As shown in Figure 6a, pretreatment of the
glEND.2 cells with ALP, but not with the irrelevant control pro-
tein hSA, was associated with a markedly decreased nuclear
NF-κB DNA-binding activity. As a control, a parallel EMSA
from the same experiment showing the electrophoretic mobil-
ity of Oct-1 binding nuclear proteins was performed. The con-
trol EMSA exhibited neither an IL-1β-induced increase in Oct-
Figure 6
Inhibition of IL-1β-induced NF-κB activation in glEND.2 cells by ant leukoproteinase antileu-
koproteinase. (a) The left panel shows an electrophoretic mobility-shift 
assay (EMSA) performed with nuclear extracts from unstimulated con-
trol cells (lane 4) and IL-1β-stimulated glEND.2 cells that had been pre-
incubated in either the absence (lane 1) or the presence of 
antileukoproteinase (ALP; lane 2) or human serum albumin (hSA; lane 
3) as an irrelevant control protein. Pretreatment of the glEND.2 cells 
with ALP was associated with a clearly decreased nuclear translocation 
of NF-κB reflected by the weakened intensity of the corresponding 
band shifts of the radiolabelled NF-κB-specific oligonucleotides. For 
comparison a concomitantly developed EMSA from the same experi-
ment shows the electrophoretic mobility of the constitutively active tran-
scription factor Oct-1 (right panel; lanes loaded as described for the 
left panel). (b) The densitometric evaluation of an independently per-
formed EMSA experiment depicts the difference in NF-κB signal inten-
sities between unstimulated control (- IL-1β control) and IL-1β-
stimulated glEND.2 cells preincubated with either 5 µM ALP or 5 µM 
hSA. As a quantitative measure of the nuclear translocation of NFκ-B 
the figure shows the relative DNA-binding activity of NF-κB. This 
parameter represents the numerical proportion between NF-κB-binding 
and Oct-1-binding activity in c.p.m. The protein binding to the radiola-
belled specific probe for the constitutively active transcription factor 
Oct-1 served as an internal standard for normalization of the nuclear 
extracts. (c) An additional specificity control for the NF-κB EMSA. 
Before electrophoretic separation, nuclear extracts from IL-1β-stimu-
lated glEND.2 cells were incubated not only with the radiolabelled NF-
κB but also with two different concentrations of unlabelled competitor 
probes. The results of the blocking experiments of the NF-κB EMSA 
with an unlabelled NF-κB-probe (Inh) (showing blocking at 10-fold (*) 
and 100-fold (#) molar excess) and a mutant NF-κB probe (Mut) that 
did not suppress the NF-κB signal at 10-fold and 100-fold molar 
excess, respectively, are shown. Lane 1 was loaded with a sample with-
out competing probe as in (a).Page 7 of 11
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dependence on pretreatment of the cells with ALP or hSA. The
densitometric evaluation of another independently performed
EMSA experiment also revealed a clear difference in NF-κB
signal intensities between IL-1β-stimulated glEND.2 cells pre-
incubated with either ALP (5 µM) or hSA (5 µM) (Figure 6b).
We also controlled for the specificity of the NF-κB EMSA by
competition experiments containing the radiolabelled NF-κB
probe and unlabelled probes. The results of the blocking
experiments of the NF-κB EMSA with an unlabelled NF-κB
probe (showing blocking at 10-fold and 100-fold molar
excess) and a mutant NF-κB probe that did not suppress the
NF-κB signal at 10-fold and 100-fold molar excess, respec-
tively, are shown in Figure 6c, providing clear evidence for the
specificity of the NF-κB EMSA. To further investigate the influ-
ence of ALP on the transcriptional activity of NF-κB, endothe-
lial glEND.2 cells were transfected with an NF-κB-dependent
luciferase reporter gene and the luciferase activity in lysed
cells was quantified. As expected, the transcriptional activity of
NF-κB was strongly induced by stimulation with IL-1β. Prein-
cubation with ALP dose-dependently inhibited the IL-1β-
induced transcriptional NF-κB activity, as shown in Figure 7.
This result is in agreement with the finding of decreased
nuclear NF-κB DNA-binding activity after treatment with ALP.
Discussion
ALP has previously been shown to exert a variety of anti-inflam-
matory effects beyond its function as an inhibitor of
granulocytic serine proteinases [3-5,13]. We have recently
demonstrated its antiarthritic effect in the CAIA model as well
as a suppressive effect on immune-complex-induced activa-
tion of β2-integrins in leukocytes. Because of the modulatory
potential of ALP on the function of integrins that are crucially
involved in leukocyte extravasation [5], the present study
focused on its interference with leukocyte-endothelial-cell
interactions. Accordingly, a blocking effect of ALP on the firm
leukocyte adhesion induced by anti-CII mAb transfer in vivo
was detectable. This effect is consistent with the well estab-
lished inhibitory effect of ALP on the cytoskeletal reorganiza-
tion of stimulated granulocytes and the accompanying
suppression of conformational changes of the β2 chain of the
integrins LFA-1 (CD11a/CD18) and Mac-1 (CD11b/CD18)
[5], because the activation of these molecules is a requirement
for firm leukocyte attachment to the activated endothelial lining
[7-9]. Interestingly, a slight but significant decrease in firm leu-
kocyte adhesion to the vessel wall is also detectable in the
NaCl-control cohort during the interval between 6 and 24
hours after anti-CII antibody transfer (from 1,354 ± 125 (mean
± SEM) to 953 ± 67). However, this tendency did not con-
tinue spontaneously in the later course. Measurements of leu-
kocyte attachment at 72 hours after antibody transfer (928 ±
84) suggest that the level reached at 24 hours after an initial
decline from the early peak already represents the plateau
value that is highly elevated above normal and maintained until
at least 72 hours, a time point coinciding with first clinical
signs of arthritis in the arthritis model induced by anti-CII
antibody.
In addition to the suppression of firm leukocyte adhesion in
ALP-pretreated mice, inhibitory effects on the rolling phase of
the leukocytes along the vessel wall were observed by intravi-
tal microscopy. During an inflammatory response, leukocytes
roll along the endothelial layer of cytokine-activated venules
before they arrest, adhere and transmigrate. CD18 integrins,
as known targets of ALP action [5], have been shown to be
unable to mediate leukocyte rolling independently of selectins
[26,27]. In this respect, selectins seem to ensure an appropri-
ate decrease in rolling velocity that enables the leukocytes to
spend a critical time span in close contact with the endothe-
lium in most tissues [26]. This decelerated rolling allows proin-
flammatory cytokines to be displayed by the endothelium, for
example by means of proteoglycans [28], to engage their
Figure 7
Inhibition of IL-1β-induced NF-κB transcriptional activity in glEND.2 cells by antileukoproteinase
cells by antileukoproteinase. Effects of antileukoproteinase (ALP) on 
glEND.2 cells that had been transfected with an NF-κB-luciferase 
reporter gene construct were analysed separately. The determination of 
luminescence signals in the luciferase assay of the lysed cells permit-
ted the quantification of the IL-1β-induced upregulation of transcrip-
tional NF-êB-activity (expressed as a percentage of luminescence 
maximum). The stimulatory cytokine effect on NF-κB activation (+IL-1β) 
above the level of the unstimulated control (- IL-1β control) was signifi-
cantly suppressed by ALP (*p < 0.05) in a concentration-dependent 
manner (+IL-1β ALP 8 µM and +IL-1β ALP 20 µM). Results are means 
and SEM for 16 independent experiments.Page 8 of 11
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leading to the activation of β2-integrins. The subsequent β2-
integrin-dependent interactions with endothelial ligands (such
as ICAM-1) stabilize the retardation of rolling, provoke arrest
and cause firm adhesion as preconditions for the final transmi-
gration through the blood vessel wall [29].
In accordance with this complex interwoven action of selectins
and CD18 integrins in leukocyte rolling and adhesion, it was
consistent to propose blocking effects of ALP on leukocyte
rolling in vivo as an additional interference with selectin inter-
actions beyond the already known suppression of leukocyte
integrin activation [5]. In an in vitro assay of E-selectin-
dependent leukocyte attachment to the IL-1β-activated
glEND.2 cells, the significantly decreased adherence to the
ALP-pretreated endothelial layer provides first evidence for
ALP-induced modulation of the endothelial function of E-selec-
tin. Moreover, our investigations have elucidated a suppres-
sion of the cytokine-induced upregulation of E-selectin on the
endothelial membrane by ALP. E-selectin expression is regu-
lated primarily at the level of transcriptional activation, a proc-
ess mediated by a series of tandem NF-κB sites in the
promoter of this gene [30]. Stimuli such as IL-1β can rapidly
enhance the expression of the E-selectin gene in endothelial
cells by inducing a cytoplasmic-nuclear shuttling of NF-κB that
causes transcriptional activation on binding to the E-selectin
promoter [12,31].
Although suppressive effects of ALP on the NF-κB signalling
pathway by inhibitory mechanisms that are as yet unresolved
had already been described in other experimental systems in
vivo and in vitro [6,13], it was not at all clear that this action
also had the potential to counteract IL-β-induced endothelial
cell activation. Therefore this newly uncovered interference
with the IL-β-induced nuclear translocation of transcriptionally
active NF-κB is likely to account for the observed suppression
of cytokine-activated E-selectin upregulation by ALP. How-
ever, the precise molecular mechanism underlying the sup-
pressive effect of ALP on IL-1β-induced NF-κB activation in
endothelial cells remains enigmatic. Similarly, the suppressive
effect of ALP on lipopolysaccharide-induced NF-κB activation
in monocytic cells (U937) has been shown to imply an inhibi-
tion of the cytoplasmic degradation of IκBα. However, ALP did
not suppress the phosphorylation or ubiquitination of IκBα and
did not exhibit activities of a broad-spectrum inhibitor of the
proteasomal degradation machinery [32].
More recently, the cytoplasmic localization of ALP after rapid
uptake from the extracellular space and its subsequent trans-
location into the nucleus, associated with direct binding to
nuclear NF-κB sites, have been described in U937 cells [33].
However, we could not detect in our EMSA shifts (Figure 6a),
performed with NF-κB-specific probes, any ALP-oligonucle-
otide complexes in the expected lower molecular mass range,
rendering the possibility of direct nuclear binding of ALP to
NF-κB sites and thus competition with p65 interaction a rather
unlikely explanation for our results obtained in endothelial cells.
Whether ALP induces other IκB proteins or exerts its suppres-
sive effect on NF-κB through the activation of alternative sig-
nalling pathways remain interesting possibilities. Irrespective
of the precise mode of ALP action, NF-κB inhibition and its
closely associated suppression of cytokine-activated E-selec-
tin upregulation provide an attractive explanation for the
observed inhibitory effects on selectin-dependent leukocyte
attachment to murine glEND.2 and human EA.hy 926 cells in
vitro. Moreover, it is rather likely that modulation of selectins is
also involved in decreased leukocyte rolling after anti-CII mAb
transfer in ALP-treated mice in comparison with the control in
vivo. In addition, the suppression by ALP of IL-1β-induced NF-
κB signalling is likely to have a much broader spectrum of anti-
inflammatory effects on the endothelial cells than the downreg-
ulation of E-selectin expression investigated as an example
because the inhibited signalling pathway is critical for the
upregulation of a plethora of adhesion molecules and inflam-
matory mediators [34].
This broad suppressive effect on the activation of the endothe-
lial layer cooperates with already known properties of ALP to
downmodulate β2-integrin-dependent proinflammatory func-
tions in leukocytes [5] to counteract leukocyte extravasation.
Indeed, this inhibitory effect of ALP on leukocytic tissue infiltra-
tion has already been demonstrated in a variety of models
such as streptococcal cell wall arthritis [13], CAIA [5], reverse
passive cutaneous Arthus reaction (B. Sehnert, A. Cavcic, and
H. Burkhardt, unpublished results) and inflammatory organ
injury in a murine ischaemia/reperfusion model [14]. This
potential of ALP to inhibit leukocyte extravasation in response
to quite diverse inflammatory stimuli suggests its extended role
as a regulatory molecule of innate immunity. Of course, inter-
esting questions remain to be answered in further studies: the
effect of ALP on the regulation of anti-inflammatory cytokines
such as TGF-β, on vascular permeability or its potential to
interfere with trafficking of other cells of the innate and adap-
tive immune system such as lymphocytes, monocytes, den-
dritic cells and mast cells. The answers to these questions will
help in judging therapeutic potential in future treatment strate-
gies. However, the effect of ALP on both β2-integrins on leu-
kocytes and endothelial cell adhesion molecules such as E-
selectin suggests a modulatory role of cell-cell adhesion
mechanisms without complete suppression, because other-
wise the combination of blocking selectins and integrins would
result in a complete lack of polymorphonuclear cells adhesion.
ALP therefore offers an attractive possibility for modulating the
immune response. In this respect our work has uncovered for
the first time the suppressive effects of ALP on selectin-
dependent and integrin-dependent leukocyte adhesion events
to the vessel walls that cooperate in the prevention of subse-
quent leukodiapedesis.Page 9 of 11
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The newly uncovered ability of ALP to interfere with cytokine
signalling and with the upregulation of adhesion molecules in
endothelial cells probably contribute to its protective effects
on immune-complex-mediated tissue injury. These new
insights into the spectrum of anti-inflammatory actions of ALP
might prove useful in the development of therapeutic interven-
tions in endothelial barrier dysfunction caused by misdirected
leukocyte activation in the joints or at extra-articular sites of
immune-complex deposition in systemic disease.
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